Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 1
2012 1
2018 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis.
McCann FE, Palfreeman AC, Andrews M, Perocheau DP, Inglis JJ, Schafer P, Feldmann M, Williams RO, Brennan FM. McCann FE, et al. Arthritis Res Ther. 2010;12(3):R107. doi: 10.1186/ar3041. Epub 2010 Jun 2. Arthritis Res Ther. 2010. PMID: 20525198 Free PMC article.
Inhibition of PDE4 has previously been shown to suppress immune and inflammatory responses, demonstrating PDE4 to be a valid therapeutic target for immune-mediated pathologies. We assessed the anti-inflammatory effects of a …
Inhibition of PDE4 has previously been shown to suppress immune and inflammatory responses, demonstrating …
Apremilast Ameliorates Experimental Arthritis via Suppression of Th1 and Th17 Cells and Enhancement of CD4(+)Foxp3(+) Regulatory T Cells Differentiation.
Chen W, Wang J, Xu Z, Huang F, Qian W, Ma J, Wee HB, Lewis GS, June RR, Schafer PH, Lin J, Zheng SG. Chen W, et al. Front Immunol. 2018 Jul 18;9:1662. doi: 10.3389/fimmu.2018.01662. eCollection 2018. Front Immunol. 2018. PMID: 30072998 Free PMC article.
Apremilast is a novel phosphodiesterase 4 (PDE4) inhibitor suppressing immune and inflammatory responses. ...To determine whether Apremilast can ameliorate arthritis onset in this model, Apremilast …
Apremilast is a novel phosphodiesterase 4 (PDE4) inhibitor suppressing immune and …
Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study.
De Souza A, Strober BE, Merola JF, Oliver S, Franks AG Jr. De Souza A, et al. J Drugs Dermatol. 2012 Oct;11(10):1224-6. J Drugs Dermatol. 2012. PMID: 23134988 Clinical Trial.
BACKGROUND: Discoid lupus erythematosus (DLE) is a chronic inflammatory disorder mediated by Th1 cells. Apremilast is a novel oral PDE4 enzyme inhibitor capable of blocking leukocyte production of IL-12, IL-23, TNF-a, INF- with subsequent sup …
BACKGROUND: Discoid lupus erythematosus (DLE) is a chronic inflammatory disorder mediated by Th1 cells. Apremilast is a nov …
Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?
Giembycz MA. Giembycz MA. Br J Pharmacol. 2008 Oct;155(3):288-90. doi: 10.1038/bjp.2008.297. Epub 2008 Jul 28. Br J Pharmacol. 2008. PMID: 18660832 Free PMC article.
PDE4 inhibitors have been in development as a novel anti-inflammatory therapy since the 1980s with asthma and chronic obstructive pulmonary disease (COPD) being primary indications. ...In addition, other approaches are possible that may allow the anti-infl …
PDE4 inhibitors have been in development as a novel anti-inflammatory therapy since the 1980s with asthma and chronic o …